SI2148876T1 - Pirazolonski derivati kot PDE4 inhibitorji - Google Patents

Pirazolonski derivati kot PDE4 inhibitorji

Info

Publication number
SI2148876T1
SI2148876T1 SI200830491T SI200830491T SI2148876T1 SI 2148876 T1 SI2148876 T1 SI 2148876T1 SI 200830491 T SI200830491 T SI 200830491T SI 200830491 T SI200830491 T SI 200830491T SI 2148876 T1 SI2148876 T1 SI 2148876T1
Authority
SI
Slovenia
Prior art keywords
pde4 inhibitors
pyrazolone derivatives
pyrazolone
derivatives
pde4
Prior art date
Application number
SI200830491T
Other languages
English (en)
Inventor
Beate Schmidt
Christian Scheufler
Jurgen Volz
Martin P Feth
Rolf-Peter Hummel
Armin Hatzelmann
Christof Zitt
Andrea Wohlsen
Degenhard Marx
Hans-Peter Kley
Deborah Ockert
Anke Heuser
Johannes A M Christiaans
Geert Jan Sterk
Wiro M P B Menge
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of SI2148876T1 publication Critical patent/SI2148876T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
SI200830491T 2007-05-16 2008-05-14 Pirazolonski derivati kot PDE4 inhibitorji SI2148876T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07108314 2007-05-16
PCT/EP2008/055867 WO2008138939A1 (en) 2007-05-16 2008-05-14 Pyrazolone derivatives as pde4 inhibitors
EP08759563A EP2148876B1 (en) 2007-05-16 2008-05-14 Pyrazolone derivatives as pde4 inhibitors

Publications (1)

Publication Number Publication Date
SI2148876T1 true SI2148876T1 (sl) 2012-01-31

Family

ID=38179942

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830491T SI2148876T1 (sl) 2007-05-16 2008-05-14 Pirazolonski derivati kot PDE4 inhibitorji

Country Status (31)

Country Link
US (3) US8304436B2 (sl)
EP (3) EP2402330B1 (sl)
JP (2) JP5529010B2 (sl)
KR (1) KR101601284B1 (sl)
CN (2) CN101657441B (sl)
AR (1) AR066576A1 (sl)
AT (1) ATE526326T1 (sl)
AU (1) AU2008250069B2 (sl)
BR (1) BRPI0811214A2 (sl)
CA (1) CA2686909C (sl)
CO (1) CO6220956A2 (sl)
CY (1) CY1112152T1 (sl)
DK (1) DK2148876T3 (sl)
EA (1) EA018984B1 (sl)
EC (1) ECSP099738A (sl)
ES (2) ES2374337T3 (sl)
HK (2) HK1141017A1 (sl)
HR (1) HRP20110940T1 (sl)
IL (1) IL201959A (sl)
ME (1) ME00952B (sl)
MX (1) MX2009012062A (sl)
MY (1) MY154498A (sl)
NZ (1) NZ581547A (sl)
PL (1) PL2148876T3 (sl)
PT (1) PT2148876E (sl)
RS (1) RS52074B (sl)
SI (1) SI2148876T1 (sl)
TW (2) TWI460174B (sl)
UA (1) UA100019C2 (sl)
WO (1) WO2008138939A1 (sl)
ZA (1) ZA200906423B (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY154498A (en) * 2007-05-16 2015-06-30 Takeda Gmbh Pyrazolone derivatives as pde4 inhibitors
AR074318A1 (es) * 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
WO2010101246A1 (ja) * 2009-03-05 2010-09-10 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
JP5609614B2 (ja) * 2010-12-15 2014-10-22 東ソー株式会社 新規アリールアミンデンドリマー状化合物、その製造方法およびその用途
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2903460A (en) 1956-04-07 1959-09-08 Sandoz Ag Pyrazolone derivatives
US4550119A (en) 1983-05-23 1985-10-29 Warner-Lambert Company 2,4-Dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
JP3775684B2 (ja) 1992-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物
SI0706513T1 (sl) 1993-07-02 2002-10-31 Altana Pharma Ag Fluoroalkoksi substituirani benzamidi in njihova uporaba kot inhibitorji ciklične nukleotidne fosfodiesteraze
ATE196765T1 (de) 1994-07-22 2000-10-15 Byk Gulden Lomberg Chem Fab Dihydrobenzofurane
PT971901E (pt) * 1997-01-15 2003-07-31 Altana Pharma Ag Ftalazinonas
US6418201B1 (en) 2000-02-22 2002-07-09 Intel Corporation Multiple platform voice processing system with optimized resource allocation
KR20030074817A (ko) * 2001-02-15 2003-09-19 알타나 파마 아게 Ｐｄｅ4 억제제로서의 프탈라지논-피페리디노-유도체
IL157881A0 (en) * 2001-04-20 2004-03-28 Pfizer Prod Inc Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
NZ529221A (en) 2001-04-25 2005-04-29 Altana Pharma Ag Phthalazinones with PDE-inhibiting properties for treatment of airway disorders and other inflammatory conditions
PL373146A1 (en) 2002-08-10 2005-08-22 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
EP1537100B1 (en) * 2002-08-10 2007-04-25 ALTANA Pharma AG Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
AU2003255376A1 (en) * 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
CA2496732A1 (en) 2002-08-20 2004-03-04 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
AR045536A1 (es) * 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
EP1720854A1 (en) * 2004-02-04 2006-11-15 Altana Pharma AG Phthalzinone derivatives as pde4 inhibitors
JP4778449B2 (ja) * 2004-02-04 2011-09-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての２−（ピペリジン−４−イル）−４，５−ジヒドロ−２ｈ−ピリダジン−３−オン誘導体
JP2006169138A (ja) * 2004-12-14 2006-06-29 Kyorin Pharmaceut Co Ltd ピラゾロピリジンピラゾロン誘導体とその付加塩及びｐｄｅ阻害剤
MY154498A (en) * 2007-05-16 2015-06-30 Takeda Gmbh Pyrazolone derivatives as pde4 inhibitors

Also Published As

Publication number Publication date
IL201959A (en) 2015-04-30
US20130012544A1 (en) 2013-01-10
ECSP099738A (es) 2009-12-28
AU2008250069B2 (en) 2013-07-25
JP2010526852A (ja) 2010-08-05
US20140378509A1 (en) 2014-12-25
JP2014159452A (ja) 2014-09-04
PL2148876T3 (pl) 2012-02-29
US9090597B2 (en) 2015-07-28
ZA200906423B (en) 2010-06-30
HK1141017A1 (en) 2010-10-29
UA100019C2 (en) 2012-11-12
KR20100017745A (ko) 2010-02-16
JP5529010B2 (ja) 2014-06-25
ES2427442T3 (es) 2013-10-30
KR101601284B1 (ko) 2016-03-08
RS52074B (en) 2012-06-30
HRP20110940T1 (hr) 2012-01-31
EP2148876B1 (en) 2011-09-28
US20100120757A1 (en) 2010-05-13
NZ581547A (en) 2012-02-24
US8865745B2 (en) 2014-10-21
AR066576A1 (es) 2009-08-26
US8304436B2 (en) 2012-11-06
CN101657441A (zh) 2010-02-24
EP2402330A1 (en) 2012-01-04
CA2686909C (en) 2016-07-05
EP2402330B1 (en) 2013-06-26
ES2374337T3 (es) 2012-02-15
AU2008250069A1 (en) 2008-11-20
DK2148876T3 (da) 2012-01-16
CO6220956A2 (es) 2010-11-19
WO2008138939A1 (en) 2008-11-20
TWI414521B (zh) 2013-11-11
ME00952B (me) 2012-06-20
MY154498A (en) 2015-06-30
TW201406752A (zh) 2014-02-16
EP2148876A1 (en) 2010-02-03
CN103463086B (zh) 2015-10-21
TWI460174B (zh) 2014-11-11
CN101657441B (zh) 2013-09-11
PT2148876E (pt) 2011-12-28
ATE526326T1 (de) 2011-10-15
TW200914439A (en) 2009-04-01
BRPI0811214A2 (pt) 2014-10-29
MX2009012062A (es) 2009-11-19
EA200901504A1 (ru) 2010-04-30
CY1112152T1 (el) 2015-12-09
IL201959A0 (en) 2010-06-16
CN103463086A (zh) 2013-12-25
EA018984B1 (ru) 2013-12-30
CA2686909A1 (en) 2008-11-20
HK1191574A1 (zh) 2014-08-01
EP2508520A1 (en) 2012-10-10
JP5850972B2 (ja) 2016-02-03

Similar Documents

Publication Publication Date Title
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
IL205142A0 (en) Pyridazinone derivatives as parp inhibitors
HK1139137A1 (en) Acylaminopyrazoles as fgfr inhibitors
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
HK1148286A1 (en) Aminopyrazole derivatives
EP2365809B8 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
HK1191574A1 (zh) 作為 抑制劑的吡唑啉酮衍生物
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL207225A0 (en) Indazole derivatives
IL236083A (en) Phenyl-pyrazole derivatives
IL205602A0 (en) Pyrazole derivatives as 5-lo inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
EP2172458A4 (en) pyrazolone